Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Multiple Myeloma 34Lymphoma, Non-Hodgkin 30Leukemia, Myeloid, Acute 25Hodgkin Disease 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Myelodysplastic Syndromes 11Lymphoma 10Leukemia, Lymphocytic, Chronic, B-Cell 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Leukemia 6Neoplasms, Plasma Cell 5Recurrence 3Pancreatic Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Hematologic Neoplasms 3Gliosarcoma 3Glioblastoma 3Warts 2Sezary Syndrome 2Neutropenia 2Myeloproliferative Disorders 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Hairy Cell 2Infections 2Immunologic Deficiency Syndromes 2

Interventions

Temozolomide 111Radiotherapy 60Carboplatin 30Bevacizumab 30Magnetic Resonance Spectroscopy 28Carmustine 28Filgrastim 23Surgical Procedures, Operative 22Irinotecan 22Radiation 17Lomustine 16Vincristine 15Etoposide 15Specimen Handling 13Peripheral Blood Stem Cell Transplantation 13O(6)-benzylguanine 13Radiotherapy, Intensity-Modulated 12Procarbazine 11Erlotinib Hydrochloride 11Cyclophosphamide 11Chemotherapy, Adjuvant 11sargramostim 10Thiotepa 10Cisplatin 10Flucytosine 9Everolimus 9antineoplaston AS 2-1 8antineoplaston A10 8Granulocyte Colony-Stimulating Factor 8Vorinostat 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Astrocytoma × plerixafor × Clear all
NCT01339039 2017-11-17

Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma

Dana-Farber Cancer Institute

Phase 1 Terminated
26 enrolled
CNS

Astrocytoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡